


























![]()
Q1: 2026-05-05 Earnings Summary
EPS of $0.30 misses by $0.31
|
Revenue of
$173.93M
(21.18% Y/Y)
misses by $127.70K
TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call May 5, 2026 4:30 PM EDT
Company Participants
Waleed Hassanein - Founder, President, CEO & Director
Gerardo Hernandez - CFO & Treasurer
Conference Call Participants
Hannah Jeffrey - The Gilmartin Group
William Plovanic - Canaccord Genuity Corp., Research Division
Joshua Jennings - TD Cowen, Research Division
K. Gong - JPMorgan Chase & Co, Research Division
Matthew Mardula - William Blair & Company L.L.C., Research Division
Christopher Pasquale - Nephron Research LLC
Suraj Kalia - Oppenheimer & Co. Inc., Research Division
Samantha Munoz - Piper Sandler & Co., Research Division
Daniel Markowitz - Evercore ISI Institutional Equities, Research Division
David Rescott - Robert W. Baird & Co. Incorporated, Research Division
Young Li - Jefferies LLC, Research Division
Michael Matson - Needham & Company, LLC, Research Division
Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division
Presentation
Hannah Jeffrey
The Gilmartin Group
[ Audio Gap ] projections, expectations, predictions are forward-looking statements, whether because of new information, future events or developments or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, May 5, 2026.
And with that, I will now turn the call over to Waleed Hassanein, President and Chief Executive Officer.
Waleed Hassanein
Founder, President, CEO & Director
Thank you so much, Hannah. Good afternoon, everyone, and welcome to TransMedics First Quarter 2026 Earnings Call. As always, joining me today is Gerardo Hernandez, our Chief Financial Officer.
Our vision has been bold -- our vision has always been bold and growth-oriented. Since inception, TransMedics has been relentless in our pursuit to transform organ transplant therapy by increasing utilization of donor organs and improving the clinical outcomes of transplant patients throughout -- through technology and service innovation and by disrupting the status quo.
To accomplish this, we've been deliberate yet aggressive in our strategic investment in growth initiatives. We
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。